Background: MiR-483-5p was recently identified as a risk factor in the early stages of acute myocardial infarction (AMI) patients. Here, we further investigated how miR-483-5p affects cardiomyocyte apoptosis and oxidative stress under hypoxic conditions. Methods: Plasma samples were collected from AMI patients and healthy volunteers. The expression of miR-483-5p was determined using quantitative real-time PCR. An in vitro hypoxic model was constructed to mimic AMI in AC16 cells. Cell viability, apoptosis and oxidative stress biomarker levels (MDA, SOD and CAT) were respectively determined using CCK-8, flow cytometry and commercial assay kits. Results: The expression levels of miR-483-5p were significantly higher in AMI patients than in control subjects. Circulating levels of miR-483-5p positively correlated with creatine kinase MB isoform (CK-MB) and cardiac troponin I (cTnI) levels. The in vitro experiments showed that the expression levels of miR-483-5p were also upregulated in hypoxia-induced AC16 cell injury. MiR-483-5p overexpression significantly increased hypoxia-induced cardiomyocyte apoptosis and oxidative stress, while knockdown attenuated these effects. Mechanistically, miR-483-5p directly targets MAPK3 in AC16 cells. Furthermore, the protective effects of miR-483-5p knockdown against hypoxiainduced cardiomyocyte injury are partially dependent on MAPK3. Conclusions: MiR-483-5p, which targets MAPK3, might be a potential therapeutic target for the diagnosis and prevention of hypoxia-induced myocardial injury.
induced apoptosis and oxidative stress in cardiomyocytes might help in the development of effective treatments for AMI.
Emerging evidence indicates that microRNAs (miRNAs or miRs) play crucial roles in the pathogenesis of cardiovascular diseases, including AMI. For example, the expression levels of miR-1, −133a and − 499 are significantly higher in the serum of AMI patients than in that of healthy individuals [5] . MiR-223-3p contributes to ischemic arrhythmias in AMI by downregulating KCND2/Kv4.2 [6] . Shi et al. showed that miR-499-5p overexpression could attenuate hypoxia-induced cardiomyocyte injury [7] .
MiR-483-5p is a reported risk factor for cardiovascular disease [8] . Moreover, Li et al. reported that significantly elevated miR-483-5p expression is a useful early-stage clinical diagnostic in AMI patients [9] . Considering this and the role of miR-483-5p in apoptosis [10, 11] , we speculated that it might participate in hypoxia-induced apoptosis and oxidative stress in human cardiomyocytes.
Mitogen-activated protein kinases (MAPKs) are a widely conserved serine/threonine protein kinase family. They are reported to regulate various cellular processes, such as proliferation and apoptosis [12] . MAPK3, also known as extracellular-regulated protein kinase 1 (ERK1), is reportedly upregulated after miR-1 knockdown with protective effects against myocardial ischemia-reperfusion injury in rats undergoing sevoflurane preconditioning [13] . MiR-15b was also found to reduce rat cardiomyocyte apoptosis by posttranscriptionally downregulating MAPK3 [14] . However, whether MAPK3 is a functional regulator involved in the miR-483-5p-mediated regulation of hypoxia-induced cardiomyocyte apoptosis remains unclear.
In this study, we determined the circulating miR-483-5p levels in AMI patients and analyzed the correlation between miR-483-5p and myocardial injury and cardiac function. We also established a hypoxia-induced cellular model of AMI in AC16 cells to explore whether miR-483-5p affected cell functions. Furthermore, we explored the potential mechanisms underlying a miR-483-5p-MAPK3 link involved in hypoxiainduced cardiomyocyte apoptosis.
Materials and methods

Clinical specimens
A total of twenty patients angiographically diagnosed with AMI (showing at least 50% stenosis) and twenty healthy volunteers were enrolled from the Shandong Provincial Hospital Affiliated to Shandong University. The exclusion criteria included severe liver or renal function defects, acute or chronic infections, malignant tumors, cardiomyopathies, and hematological disorders. Healthy subjects also underwent routine medical examinations and were confirmed to have no medical history of heart disorders or family history of coronary heart disease. The main clinical characteristics, including CK-MB, cTnI, medical history and blood pressure, are summarized in Table 1 . Written consent was signed by all subjects before enrollment. This study was approved by the Ethics Committee of the Shandong Provincial Hospital Affiliated to Shandong University.
Plasma collection and storage
Using K2-EDTA-coated tubes, venous blood samples were collected from each participant in the morning regardless of time. Blood samples underwent centrifugation at 1000×g at 4°C for 40 min to obtain the plasma supernatant. The isolated plasma was placed into RNase/DNase-free tubes and stored at − 70°C for further analysis.
Cell culture and treatments
Cells of the human cardiomyocyte-like cell line AC16 were provided by the American Type Culture Collection (ATCC). They were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) at 37°C in an atmosphere containing 5% CO 2 . For the hypoxia experiments, the cells were transferred into a hypoxic incubator containing 1% O 2 , 94% N 2 and 5% CO 2 for 12, 24 or 48 h at 37°C. As a normoxic control, cells were cultured in a normoxic incubator (21% O 2 , 5% CO 2 and 74% N 2 ) at 37°C.
Oligonucleotide transfection
Oligonucleotides, including the miR-483-5p mimic, miR-483-5p inhibitor and negative control (miR-NC), were synthesized by RiboBio. Small interfering RNA targeting MAPK3 (si-MAPK3) and negative control siRNA (si-NC) were provided by GenePharma. For MAPK3 rescue experiments, pcDNA3.1-MAPK3 ectopic expression was achieved by sub-cloning MAPK3 cDNA into pcDNA3.1 mammalian expression vector (Invitrogen). Per manufacturer's instructions, transfection was mediated with Lipofectamine 2000 reagent (Invitrogen) for 48 h prior to 24 h exposure to hypoxic or normoxic conditions. 
Quantitative real-time PCR
Total RNA was extracted from isolated plasma and cells using TRIzol reagent (Invitrogen). A TaqMan MicroRNA Reverse Transcription kit (Tiangen Biotechnology) was used to synthesize first-strand complementary DNA (cDNA) from isolated RNA. Using a SYBR Premix Ex Taq II kit (Takara), quantitative real-time PCR ran with the following thermocycling conditions: 2 min at 50°C; 10 min at 95°C; 40 cycles of 15 s denaturation at 95°C and 60 s annealing/extension at 60°C. The primer sequences were: miR-483-5p: 5′-AGTTGGCTCACGGTTCTTTCAA-3′ (forward) and 5′-ATCGCCATGGCCCGCATG TCGG-3 (reverse); and U6: 5′-CTCGCTTCGGCAGCACA-3′ (forward) and 5′-AACGCTTCACGA ATTTGCGT-3′ (reverse). The 2 −ΔΔCT method was used to calculate the relative expression level of miR-483-5p.
Cell viability assay
Briefly, AC16 cells were seeded into 96-well plates at a density of 3000 cells per well and cultured overnight. The next day, the cells in each well were incubated with 10 μl of Cell Counting Kit-8 reagent (CCK-8; Dojindo Molecular Technologies) for another 2 h at 37°C. The optical density value at a wavelength of 450 nm was read and relative cell viability was calculated by taking the normoxia group value as 100%. Three independent assays were run for each time point.
Apoptosis assay
In brief, cells from different groups were harvested by trypsinization, washed with PBS and re-suspended in 1× binding buffer, followed by double staining with 10 μl Annexin V-FITC and 5 μl PI (Beyotime) for 10 min in darkness at 4°C. Afterwards, stained cells were examined using a flow cytometer with FlowJo software (Becton Dickinson). Three replications were prepared for each sample.
Analysis of MDA level and antioxidant enzymes
Using the relevant commercial assay kits from Nanjing Jiancheng Bioengineering Institute, we determined the level of malondialdehyde (MDA) and the activities of superoxide dismutase (SOD) and catalase (CAT) in the cellular supernatants. The MDA level was expressed as nmol/mg and the activities of SOD and CAT as units/mg. Three replications were done for each sample.
Luciferase reporter assay
The potential interaction between miR-483-5p and MAPK3 was predicted using the TargetScan7 tool (http://www.targetscan.org/vert_71/). We amplified the fragment of the MAPK3 3′-untranslated region (UTR) containing the miR-483-5p predicted seed region (wild-type; WT) from the cDNA of cells and inserted it into pmirGLO vector (Promega) with double digestion. The corresponding digestion products were recycled and connected using T4 DNA ligase. After extracting the plasmid, we acquired the corrected recombinant wild-type reporter plasmid pmirGLO-WT-MAPK3. Similarly, the corresponding mutant reporter plasmid, pmirGLO-MUT MAPK3 was also synthesized with the Site-Directed Mutagenesis Kit (Agilent Technologies). For the luciferase reporter assay, WT or MUT reporter plasmid and miR-483-5p mimic or miR-NC were co-transfected into human AC16 cells using Lipofectamine 2000 reagent (Invitrogen). Transfected cells were harvested 48 h after transfection and luciferase activity was determined with a dual-luciferase reporter system (Promega).
Western blot analysis
Cells were harvested and protein was extracted using RIPA lysis reagent with protease inhibitors (Pierce). Protein samples were quantified using a bicinchoninic acid assay protein kit (Beyotime). Equal amounts of 30 μg of total protein were separated via SDS-PAGE (10% gel), which was transferred onto PVDF membranes. The membrane was subsequently blocked for 2 h with TBS containing 5% nonfat milk and incubated at 4°C overnight with primary antibodies (Abcam) against MAPK3 and β-actin. After two washes with PBS, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology). The protein bands were visualized using an enhanced chemiluminescence kit (Beyotime) with β-actin as an internal control.
Statistical analysis
All experiments were prepared in triplicate and performed three times. Data were analyzed using SPSS 19.0 and expressed as means ± standard deviation (SD). Statistical evaluations between two groups were achieved using Student's t-test. One-way analysis of variance followed by a post hoc Tukey test was applied for comparisons among multiple groups. Spearman rank correlation analyses were performed to investigate the relationships between two groups. Statistical significance was taken as p < 0.05.
Results
The expression levels of miR-483-5p inversely correlate with those of MAPK3 in plasma samples derived from AMI patients
To explore the potential effects of miR-483-5p in the development of AMI, we determined the expression of miR-483-5p in plasma samples from twenty AMI patients and 20 healthy volunteers using quantitative real-time PCR analysis. We found the expression levels of miR-483-5p were significantly higher in AMI patients than in the control subjects ( Fig. 1a ). More importantly, correlation analysis demonstrated that miR-483-5p expression levels were positively associated with the myocardial injury markers CK-MB ( Fig. 1b ) and cTnI (Fig. 1c ) in AMI patients. In addition, we found miR-483-5p expression negatively correlated with MAPK3 mRNA in AMI patients (Fig. 1d) . These findings indicate that miR-483-5p probably plays a crucial role in the progression of AMI.
MiR-483-5p and MAPK3 expression levels are aberrantly altered in cardiomyocytes under hypoxic conditions
To investigate the function of miR-483-5p in AMI in vitro, we constructed a cardiomyocyte model for hypoxia exposure, since this is a key pathologic feature of AMI. AC16 cells were used for the model and functional tests focused followed. The CCK-8 assay showed that the cell viability of AC-16 cells significantly decreased under hypoxic conditions in a time-dependent manner ( Fig. 2a ). Because 48 h of hypoxic treatment generated a remarkable reduction in cell viability, we selected this time period for subsequent analyses.
In line with impaired cell viability, the number of apoptotic cells significantly increased in the hypoxia group compared with the normoxia group (Fig. 2b) . We also analyzed whether hypoxia induced oxidative damage in AC16 cells, observing an apparent elevation in MDA content ( Fig. 2c ) and reduction in anti-oxidative activities of SOD ( Fig. 2d ) and CAT ( Fig. 2e ) triggered by hypoxia. Interestingly, the expression levels of miR-483-5p were markedly upregulated, while MAPK3 mRNA was downregulated in cardiomyocytes under conditions of hypoxia (Fig. 2f ). These findings indicate that MiR-483-5p contributes to hypoxia-induced apoptosis and oxidative stress in cardiomyocytes Next, we performed gain-of-function and loss-of-function assays to confirm the impacts of miR-483-5p on hypoxia-induced damage in cardiomyocytes. MiR-483-5p overexpression and knockdown in AC16 cells were respectively achieved after transfection with miR-483-5p mimic and miR-483-5p inhibitor, and validated using quantitative real-time PCR (Fig. 3a) .
The results from the CCK-8 assay showed that overexpression of miR-483-5p robustly decreased cell viability, while ablation of miR-483-5p attenuated the decreased cell viability in AC16 cells under hypoxic conditions (Fig. 3b ). The hypoxia-induced apoptotic rate was consistently increased after miR-483-5p overexpression but decreased after miR-483-5p silencing (Fig. 3c) .
Additionally, the oxidative stress levels were evaluated using commercial assay kits. Our results showed that hypoxia induced upregulation of MDA content (Fig. 3d ) and downregulation of SOD ( Fig. 3e ) and CAT (Fig. 3f) activities, which were markedly enhanced after miR-483-5p mimic transfection and attenuated after miR-483-5p inhibitor transfection. These findings imply that miR-483-5p plays a positive role in hypoxiainduced cardiomyocyte injury.
MAPK3 is a direct target of miR-483-5p
The clinical samples showed miR-483-5p levels negatively correlate with MAPK3 expression in AMI patients. We thus hypothesized that MAPK3 might be directly regulated by miR-483-5p in hypoxia-induced cardiomyocyte injury. As expected, TargetS-can7 verified that miR-483-5p is predicted to partially bind to the 3′-UTR of MAPK3 (Fig. 4a ). A luciferase reporter assay was carried out to experimentally validate whether MAPK3 is a direct target of miR-483-5p. The luciferase activity of the WT MAPK3-3′-UTR reporter gene notably decreased after miR-483-5p mimic transfection, but had no obvious effect in the corresponding MUT reporter (Fig. 4b) . Furthermore, we found that the protein expression level of MAPK3 was lower under hypoxic conditions than in normoxia. The hypoxia-induced decrease in MAPK3 was aggravated by miR-483-5p overexpression, but augmented by miR-483-5p knockdown (Fig. 4c) . These results show that miR-483-5p repressed MAPK3 expression by directly binding its 3′-UTR.
Restoration of MAPK3 imitates the effects of an miR-483-5p inhibitor in cardiomyocytes exposed to hypoxia Based on the downregulation of MAPK3 in cardiomyocytes under hypoxic conditions, we performed gain-of-function assays to investigate the functional role of MAPK3 in hypoxia-injured AC16 cells. AC16 cells were transfected with pcDNA3.1-MAPK3 or pcDNA3.1 before culture under hypoxic conditions. The protein expression of MAPK3 was confirmed to be obviously elevated after pcDNA3.1-MAPK3 transfection in the hypoxia-injured cardiomyocytes (Fig. 5a ). Similarly to the impact of miR-483-5p inhibitor transfection, MAPK3 overexpression significantly increased cell viability ( Fig. 5b) and reduced the number of apoptotic cells ( Fig. 5c and d) . In addition, upregulation of MAPK3 partially reduced MDA content (Fig. 5e ), but restored SOD (Fig. 5f ) and CAT (Fig. 5g ) following exposure to hypoxia.
Knockdown of MAPK3 abolishes the effects of miR-483-5p inhibitor in cardiomyocytes under hypoxic conditions
To further elucidate whether miR-483-5p regulates cardiomyocyte apoptosis and oxidative damage by targeting MAPK3 during hypoxia, rescue experiments were conducted in AC16 cells. Western blot analysis validated that co-transfection with si-MAPK3 and Fig. 4 MiR-483-5p directly targets MAPK3 in AC16 cells subjected to hypoxia. a The predicted binding sites for miR-483-5p in the WT and MUT 3′-UTR of MAPK3. b Luciferase activity was measured using a luciferase reporter assay. Data are indicated as means ± SD of three independent experiments. **p < 0.01, as compared with miR-NC. c AC16 cells were transfected with miR-483-5p mimic or inhibitor, followed by 24 h hypoxia treatment. The protein level of MAPK3 was determined via western blot assay miR-483-5p inhibitor downregulated the expression of MAPK3 compared with cells transfected with the miR-483-5p inhibitor alone (Fig. 6a) . The CCK-8 assay (Fig. 6b ) and flow cytometry assay ( Fig. 6c and d) showed that MAPK3 knockdown markedly reversed the increased cell viability and the decreased apoptosis induced by the miR-483-5p inhibitor. In addition, depletion of MAPK3 significantly attenuated the MDA content ( Fig. 6e ) and anti-oxidative activities of SOD ( Fig. 6f ) and CAT (Fig. 6g ) in hypoxia-injured AC16 cells. These results show that miR-483-5p knockdown could upregulate MAPK3 to attenuate hypoxia-induced apoptosis and oxidative stress.
Discussion
We found that the miR-483-5p expression level was significantly higher in AMI patients than in healthy volunteers. Correlation analyses showed circulating levels of miR-483-5p positively correlated with the levels of creatine kinase MB isoform (CK-MB) and cardiac troponin I (cTnI), which supports the potential clinical value of circulating miR-483-5p as a biomarker for AMI. As described by Li et al [9] , miR-483-5p may provide useful clinical information for diagnosis in patients with suspected AMI. CK-MB and cTnI are the current clinical blood biomarker standards for assessing severity of myocardium injury [15] . However, several shortcomings, including slow release patterns and limitations in specificity, make them insufficiently sensitive for use as a biochemical marker for the clinical diagnosis of AMI [16, 17] . Thus, the discovery of miR-483-5p might open new possibilities in the clinical diagnosis for AMI.
We then confirmed that miR-483-5p is upregulated in AC16 cells by constructing an in vitro model of hypoxia. MiR-483-5p knockdown elevated cell viability and reduced cell apoptosis in hypoxia-injured AC16 cells. To the best of our knowledge, myocardial apoptosis has been extensively researched in terms of its effect on cardiomyocyte death and survival [18, 19] . Consistent with our findings, previous studies reported that miR-483-5p decreased radiation-induced apoptosis and DNA damage in nasopharyngeal carcinoma cells [10] , and regulated cisplatin sensitivity in tongue squamous cell carcinoma [20] . Oxidative stress is a major cause of myocardial apoptosis in the heart-damaging events [4, 21] . To explore whether elevated apoptosis was accompanied by enhanced oxidative stress in AC16 cells under hypoxic conditions, we analyzed several oxidative stress markers, including MDA, a product of lipid oxidation and the antioxidants SOD and CAT. Our results show miR-483-5p contributes to hypoxia-induced oxidative stress in AC16 cells, as reflected by the decreased MDA content and elevated activities of SOD and CAT. Liu et al previously demonstrated that antioxidant-induced ROS can lead to cardiomyocyte dysfunction through cardiac apoptosis and the activation of several maladaptive cascades [22] . We thus speculated that silencing of miR-483-5p protects cardiomyocytes against hypoxia injury by suppressing apoptosis and oxidative stress.
Importantly, we proved that miR-483-5p could bind to the 3′-UTR of MAPK3 and that the levels of MAPK3 were negatively regulated by miR-483-5p in hypoxia-injured AC16 cells. Furthermore, we demonstrated that MAPK3 was an important regulator after miR-483-5p inhibition, exerting protective effects against hypoxia-induced injury. In fact, the expression level of MAPK was significantly downregulated in response to hypoxia [23] . MAPK3 was demonstrated to play a protective role in apoptosis and oxidative damage [24, 25] . Notably, downregulation of MAPK3 by miR-15b is associated with ameliorated cardiomyocyte injury induced by hypoxia [14] . Hao et al. [13] also showed that inhibition of miR-1 promotes MAPK3 to decrease myocardial ischemiareperfusion injury in rats undergoing sevoflurane preconditioning. Moreover, MAPK3 has been demonstrated to play a protective role in cardiomyocyte apoptosis [24] . Here, miR-483-5p might be another upstream regulator of MAPK3 in hypoxia-injured AC16 cells/AC16 cells injured by hypoxia.
Conclusions
Our study reveals that miR-483-5p might be a potential biomarker for AMI. It targets MAPK3 in hypoxia-injured human cadiomyocytes/human cardiomyocytes under hypoxia, decreasing apoptosis and oxidative stress. Based on our results, inhibition of miR- Fig. 6 MAPK3 was required for the protective effects of miR-483-5p inhibition against hypoxic cardiomyocytes. AC16 cells were co-transfected with miR-483-5p inhibitor and si-MAPK3 or si-NC, followed by 24 h hypoxia treatment. a Western blotting was performed to determine the protein expression of MAPK3. b Cell viability was measured using a CCK-8 assay. c and d Cell apoptosis was analyzed using flow cytometry with double Annexin V FITC-PI staining. e through g The content of MDA, the activities SOD and CAT were measured using commercial assay kits. Data are indicated as means ± SD of three independent experiments. **p < 0.01, ***p < 0.001, as compared with miR-483-5p inhibitor + si-NC 483-5p or overexpression of MAPK3 may provide a novel way to attenuate cardiac infarction and dysfunction, although further study of the in vivo effect is needed.
Abbreviations AMI: Acute myocardial infarction; ATCC: American Type Culture Collection; DMEM: Dulbecco's modified Eagle's medium; FBS: Fetal bovine serum; MAPK3: Mitogen-activated protein kinases; SDS-PAGE: Sodium dodecyl sulfatepolyacrylamide gel electrophoresis
